128 related articles for article (PubMed ID: 18391999)
1. Can 'double blockbuster' strengthen Amgen's backbone?
Sheridan C
Nat Biotechnol; 2008 Apr; 26(4):361-3. PubMed ID: 18391999
[No Abstract] [Full Text] [Related]
2. Next-generation monoclonals less profitable than trailblazers?
Mitchell P
Nat Biotechnol; 2005 Aug; 23(8):906. PubMed ID: 16082347
[No Abstract] [Full Text] [Related]
3. GlaxoSmithKline cancer drug threatens Herceptin market.
Waltz E
Nat Biotechnol; 2005 Dec; 23(12):1453-4. PubMed ID: 16333273
[No Abstract] [Full Text] [Related]
4. Tysabri back on market.
Sheridan C
Nat Biotechnol; 2006 Aug; 24(8):874. PubMed ID: 16900111
[No Abstract] [Full Text] [Related]
5. Suicidal thoughts end Amgen's blockbuster aspirations for psoriasis drug.
Schmidt C
Nat Biotechnol; 2015 Sep; 33(9):894-5. PubMed ID: 26348946
[No Abstract] [Full Text] [Related]
6. Monoclonal antibody successes in the clinic.
Reichert JM; Rosensweig CJ; Faden LB; Dewitz MC
Nat Biotechnol; 2005 Sep; 23(9):1073-8. PubMed ID: 16151394
[TBL] [Abstract][Full Text] [Related]
7. Study critiques corporate control of trials.
Niiler E
Nat Biotechnol; 2002 Dec; 20(12):1180. PubMed ID: 12454659
[No Abstract] [Full Text] [Related]
8. Amgen's big-ticket play for Immunex.
Fletcher L
Nat Biotechnol; 2002 Feb; 20(2):105-6. PubMed ID: 11821840
[No Abstract] [Full Text] [Related]
9. Just mad about mAbs.
Jacobs T
Nat Biotechnol; 2002 Sep; 20(9):869. PubMed ID: 12205498
[No Abstract] [Full Text] [Related]
10. Amgen's Japan deal.
Ratner M
Nat Biotechnol; 2008 Apr; 26(4):366. PubMed ID: 18392006
[No Abstract] [Full Text] [Related]
11. Amgen's NESP victory cuts out Johnson & Johnson.
Fürst I
Nat Biotechnol; 1999 Feb; 17(2):124. PubMed ID: 10052335
[No Abstract] [Full Text] [Related]
12. CD20 blockers eye crowded rheumatology market.
Mack GS
Nat Biotechnol; 2008 Oct; 26(10):1053-4. PubMed ID: 18846053
[No Abstract] [Full Text] [Related]
13. Can next-generation antibodies offset biosimilar competition?
Mullard A
Nat Rev Drug Discov; 2012 Jun; 11(6):426-8. PubMed ID: 22653202
[No Abstract] [Full Text] [Related]
14. Findings halt clinical trials of centoxin.
Wagner M
Mod Healthc; 1993 Jan; 23(4):16. PubMed ID: 10123669
[No Abstract] [Full Text] [Related]
15. Marc Kirschner. Interview by Asher Mullard.
Kirschner M
Nat Rev Drug Discov; 2011 Dec; 10(12):894. PubMed ID: 22129982
[No Abstract] [Full Text] [Related]
16. What's fueling the biotech engine-2007.
Aggarwal S
Nat Biotechnol; 2008 Nov; 26(11):1227-33. PubMed ID: 18997759
[No Abstract] [Full Text] [Related]
17. Trial watch: Phase III success for Biogen's oral multiple sclerosis therapy.
Nat Rev Drug Discov; 2011 Jun; 10(6):404. PubMed ID: 21629281
[No Abstract] [Full Text] [Related]
18. Biologicals: new horizons in pharmaceutical development.
Oldham RK
J Biol Response Mod; 1983; 2(3):199-206. PubMed ID: 6358418
[No Abstract] [Full Text] [Related]
19. Market watch : Pharma industry strategic performance: 2007-2012E.
Goodman M
Nat Rev Drug Discov; 2008 Dec; 7(12):967. PubMed ID: 19043444
[No Abstract] [Full Text] [Related]
20. Monoclonals expand into neural disorders.
Vastag B
Nat Biotechnol; 2006 Jun; 24(6):595-6. PubMed ID: 16763572
[No Abstract] [Full Text] [Related]
[Next] [New Search]
